Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8193185 | PMC |
| http://dx.doi.org/10.1017/dmp.2021.124 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study.
Cancer Med
February 2025
Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Introduction: Immune checkpoint inhibitors (ICI) have improved the therapeutic arsenal in outpatient oncology care; however, data on necessity of hospitalizations associated with immune-related adverse events (irAEs) are scarce. Here, we characterized hospitalizations of patients undergoing ICI, from the prospective cohort study of the immune cooperative oncology group (ICOG) Hannover.
Methods: Between 12/2019 and 06/2022, 237 patients were included.
Association between blood test indicators and atrial fibrillation in elderly patients aged 65 and above in the Central Jiangsu region: a cross-sectional study.
BMC Cardiovasc Disord
January 2025
Department of Cardiology, Northern Jiangsu People's Hospital, Nantong West Road No. 98, Yangzhou, Jiangsu, 225001, China.
Objectives: The aim of this study was to explore the correlation between blood test indicators and Atrial Fibrillation (AF) in Individuals Aged 65 and Older in Yangzhou, Jiangsu.
Methods: From January 1, 2019, to August 31, 2023, an epidemiological cross-sectional survey was conducted among the elderly population undergoing health check-ups at Northern Jiangsu People's Hospital in Jiangsu Province. Patients diagnosed with AF after a 12-lead electrocardiogram were included in the case group, and non-AF individuals matched by age and gender in a 1:4 frequency ratio were included in the control group.
Global, regional, and national burden of esophageal cancer using the 2019 global burden of disease study.
Sci Rep
January 2025
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.
Esophageal cancer, with its aggressive nature and high mortality, poses diverse epidemiological challenges worldwide. Over the past three decades, esophageal cancer has exhibited a substantial global burden, marked by a significant increase in absolute numbers, contrasting with a decline in age-standardized metrics. Prevalence nearly doubled, reaching 0.
View Article and Find Full Text PDFA comprehensive analysis of trends in the burden of gout in China and globally from 1990 to 2021.
Sci Rep
January 2025
Panzhihua Central Hospital, No. 34, Yikang Street, East District, Panzhihua City, 617067, Sichuan Province, China.
Gout is a prevalent metabolic disorder characterized by urate crystal accumulation in joints, leading to acute arthritis and tophi formation. Despite advancements in management, the incidence and prevalence of gout have been increasing globally, particularly in China. This study analyzed data from the Global Burden of Disease Injuries and Risk Factors Study (GBD) to evaluate trends in gout from 1990 to 2021.
View Article and Find Full Text PDFGlobal impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: the PSERENADE project.
J Infect
January 2025
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States.
Background: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13 impact on pneumococcal meningitis incidence globally.
Methods: The number of cases with serotyped pneumococci detected in cerebrospinal fluid and population denominators were obtained from surveillance sites globally.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!